Wedbush Maintains a Buy on MannKind Corporation (MNKD)

MannKind Corporation (NASDAQ:MNKD) is one of the best strong buy penny stocks to buy now. In a report released on July 29, Yun Zhong from Wedbush maintained a Buy rating on MannKind Corporation (NASDAQ:MNKD) with a price target of $11.00.

The analyst told investors that MannKind Corporation’s (NASDAQ:MNKD) partner, United Therapeutics, has exhibited solid performance with its product Tyvaso DPI, supported by a competitive market edge and notable revenue growth.

Zhong attributed this growth to strategic pricing and a rise in patient numbers, factors that point to a strong demand for the product.

The analyst added that MannKind Corporation’s (NASDAQ:MNKD) own pipeline also presents significant expansion opportunities, especially the MNKD-201 program for idiopathic pulmonary fibrosis (IPF).

MannKind Corporation (NASDAQ:MNKD) is a biopharmaceutical company that develops and commercializes innovative therapeutic devices and products that address serious unmet medical needs for endocrine and orphan lung diseases.

The company’s pipeline and products include Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, MNKD-101, MNKD-201, MNKD-301, and MNKD-501.

While we acknowledge the potential of MNKD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.